Optimal Dosing of the Poly(ADP-Ribose) Polymerase Inhibitor Niraparib

Expert commentary on the use of PARP inhibitors as frontline maintenance therapy in the treatment of ovarian cancer, from Clinical Care Options

Ursula Matulonis, MD Released: January 11, 2021

In this slideset, CCO’s expert faculty explores the role of biomarkers and HRD when treating patients with ovarian cancer using PARP inhibitors

Alexandra Leary, MD, PhD Released: December 22, 2020

CCO’s expert faculty reviews PARP inhibitors in the treatment of patients with recurrent ovarian cancer.

Ursula Matulonis, MD Released: December 22, 2020

CCO’s expert faculty reviews the different PARP inhibitors in the treatment of patients with newly diagnosed ovarian cancer.

Prof Ignace Vergote Released: December 22, 2020